Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports.

Abstract

Anti-myelin-associated glycoprotein (MAG) neuropathy is a primary demyelinating sensorimotor polyneuropathy that can be very debilitating and is known to be resistant to treatment. There are only a few conflicting reports on the effect of Rituximab in anti-MAG neuropathy. We present three patients who improved remarkably with Rituximab infusions. Until the safety and efficacy of this drug are determined in larger controlled studies, use of Rituximab should be limited to patients with significant neurologic deficits.

• Authors: Nizar Souayah, Raje Noopur, Peter Siao Tick-Chong
• Journal: Immunopharmacology and immunotoxicology (Immunopharmacol Immunotoxicol) Vol. 35 Issue 5 Pg. 622-4 (Oct 2013) ISSN: 1532-2513 [Electronic] England
• PMID: 23944288 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Immunologic Factors
• MAG protein, human
• Myelin-Associated Glycoprotein
• Rituximab

Topics

• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Humans
• Immunologic Factors (administration & dosage)
• Male
• Middle Aged
• Myelin-Associated Glycoprotein (immunology)
• Polyradiculoneuropathy (drug therapy, immunology)
• Rituximab